X-linked sideroblastic anemia due to ALAS2 intron 1 enhancer element GATA-binding site mutations.

Autor: Campagna DR; Department of Pathology, Boston Children's Hospital, Boston, Massachusetts., de Bie CI, Schmitz-Abe K, Sweeney M, Sendamarai AK, Schmidt PJ, Heeney MM, Yntema HG, Kannengiesser C, Grandchamp B, Niemeyer CM, Knoers NV, Swart S, Marron G, van Wijk R, Raymakers RA, May A, Markianos K, Bottomley SS, Swinkels DW, Fleming MD
Jazyk: angličtina
Zdroj: American journal of hematology [Am J Hematol] 2014 Mar; Vol. 89 (3), pp. 315-9. Date of Electronic Publication: 2013 Nov 20.
DOI: 10.1002/ajh.23616
Abstrakt: X-linked sideroblastic anemia (XLSA) is the most common form of congenital sideroblastic anemia. In affected males, it is uniformly associated with partial loss-of-function missense mutations in the erythroid-specific heme biosynthesis protein 5-aminolevulinate synthase 2 (ALAS2). Here, we report five families with XLSA owing to mutations in a GATA transcription factor binding site located in a transcriptional enhancer element in intron 1 of the ALAS2 gene. As such, this study defines a new class of mutations that should be evaluated in patients undergoing genetic testing for a suspected diagnosis of XLSA.
(Copyright © 2013 Wiley Periodicals, Inc.)
Databáze: MEDLINE
Externí odkaz: